国际知名的生物医药媒体Endpoints News高级编辑Max Gelman发文报道了三迭纪与BioNTech达成研究合作与平台技术许可协议消息：

BioNTech is partnering with a 3D printing company to work on better delivering its RNA-based treatments.

The Covid-19 vaccine maker is paying $10 million upfront to Triastek, a company based in Nanjing, China, to collaborate on oral RNA drugs using 3D printing technology. If all milestones in the deal are reached, BioNTech will be on the hook for more than $1.2 billion.

BioNTech and Triastek will primarily focus on making oral RNA drugs that can get “across gastrointestinal mucosa, minimizing degradation in the gastrointestinal tract, and delivering RNA therapeutics to the portion of the gastrointestinal tract where absorption will potentially be the greatest,” according to a Tuesday press release.

Since the Covid-19 pandemic, BioNTech has attempted to broaden its reach beyond vaccines and infectious disease. The company has invested heavily in oncology and antibody-drug conjugates, as well as other technologies like artificial intelligence.

3D printing hasn’t had much breakthrough into the biopharma industry yet, however. Relatively few companies are working on such technology or have signed similar collaboration deals. Johnson & Johnson did partner with Welsh startup Midatech, according to a 2022 announcement, but no financials were disclosed at the time.

Triastek has raised more than $102 million since its founding in 2015, according to PitchBook data. It last raised money in September 2023, pulling together $20.4 million in what it called a “pre-C” financing round. Investors included Guoxin Investment, Goldmine and Morningside Venture Capital.

关于Endpoints

Endpoints News是国际知名的生物医药媒体，聚焦全球生物技术公司和制药企业，以“快速、准确”的报道风格覆盖全球生物医药行业的重大事件，获得了全球医药行业人员的高度关注和认可，也是最受中国读者关注和喜爱的医药专业媒体之一。

原文链接: BioNTech signs 3D printing deal to develop oral RNA drugs